Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides are characterized by inflammation of blood vessels, which can lead to severe organ and tissue damage. Previously considered life-threatening, they are now treated using remission induction and maintenance therapies. This article outlines the current treatment regimens, reviews clinical trial data, and discusses new developments in the treatment of ANCA-associated vasculitides.
- Ulf Schönermarck
- Wolfgang L. Gross
- Kirsten de Groot